Inotek Pharmaceuticals Presents Preclinical Data at ARVO Confirming That INO-8875 Lowers IOP by Increasing Outflow Through the Trabecular Meshwork

May 4, 2010

INO-8875 to Begin Phase 2 Trials in Glaucoma in Mid-2010

LEXINGTON, MA--(Marketwire - May 4, 2010) -  Inotek Pharmaceuticals Corp., a leader in the development of innovative drug candidates to address significant diseases of the eye, today presented results confirming the mechanism of action of the Company's lead glaucoma candidate, INO-8875, as a trabecular meshwork outflow enhancer. Studies were conducted in human trabecular meshwork cells and multiple preclinical models. INO-8875 has successfully completed a single-dose Phase 1/2 trial in glaucoma and is expected to enter Phase 2 trials with an eye-drop formulation in mid-2010. The data was presented in a poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Ft. Lauderdale, FL.

Highlights from the ARVO poster titled, "INO-8875, an Adenosine A1 Agonist, Lowers Intraocular Pressure Through the Conventional Outflow Pathway" included:

*INO-8875 in an eye-drop formulation dose-dependently lowered intraocular pressure (IOP) by 20-25% from baseline at 1-2 hours after single doses in normotensive eyes. The IOP-lowering effect of INO-8875 was sustained for 4-6 hours post-dose.


*In human trabecular meshwork cells, INO-8875 rapidly activated the extracellular signal-regulated kinases 1/2 and stimulated the release of matrix metalloproteinase-2 (MMP-2). MMP-2 is thought to be a key player in the processing of extracellular matrix that can accumulate in the trabecular meshwork and impede aqueous humor outflow.

*In isolated, perfused anterior segments of the eye, INO-8875 significantly increased conventional outflow (i.e., outflow through the trabecular meshwork) compared to vehicle.

"These data strongly support INO-8875's potential as a first-in-class product candidate for the treatment of glaucoma," stated Paul G. Howes, Inotek's President and Chief Executive Officer. "INO-8875's elegant mechanism of action utilizes the main pathway used by healthy elderly eyes to maintain normal IOP -- the trabecular meshwork. By delivering the drug directly to the tissue of the trabecular meshwork, INO-8875 is able to increase outflow there, while keeping systemic exposure to the drug low. Based on these findings and the positive results from our single-dose clinical trial of INO-8875 in glaucoma, we plan to initiate our first multiple-dose Phase 2 clinical trial of INO-8875 in glaucoma in mid-2010."

About Inotek
Inotek is a leader in the development of innovative drug candidates that address significant diseases of the eye, with a major focus on glaucoma. Inotek's lead product candidate INO-8875 is a potential first-in-class eye-drop treatment for glaucoma that significantly reduced intraocular pressure (IOP) in glaucoma subjects following single doses applied to the eye in a Phase 1/2 clinical trial. The Company believes INO-8875 will be a breakthrough treatment that can be used alone or combined with other IOP-lowering products because it increases the outflow of aqueous humor through the trabecular meshwork, the primary drainage system used by healthy elderly eyes to maintain normal IOP. The Company is also advancing a broad pipeline of PARP inhibitors and SOD mimetics that alleviate oxidative injury and inflammation, which it believes may address significant unmet medical needs in retinal diseases, such as the dry form of age-related macular degeneration (dry AMD). The Company is located in Lexington, MA. For further information on Inotek, please visit www.inotekcorp.com.

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.